Practice-changing study offers new option for tough breast cancer cases

Related posts:

1. Targeted drug can ‘diminish the suffering’ of myelofibrosis Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. ...
2. Altered pain processing in patients with cognitive impairment People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review. ...
3. Blood pressure medications can lead to increased risk of stroke The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new research. ...
4. Dying cells can protect their stem cells from destruction An SOS signal from dying daughter cells allows their mother stem cells to protect themselves from radiation and chemotherapy damageCells dying as the result of radiation exposure or chemotherapy... ...
5. Human Hendra drug, treatment not prevention In a world first in the battle against the deadly Hendra virus, volunteers are being recruited to trial a human treatment for the virus. ...